Beste apotheek van Nederland

Moxisylate versus placebo. One trial compared the efficacy and harms for moxisylate
versus placebo. 285
Harms. Participants receiving moxisylate reported prolonged erection (1.6 percent), pain (3.3
percent), faintness (3.3 percent), hypotension/nausea/bradycardia (1.6 percent) and hot flushes
(1.6 percent). Though no participants receiving placebo experienced any of these side effects,
these differences were not statistically significant.
Efficacy. In total, 86.9 versus 27.9 percent of moxisylate and placebo participants,
respectively, reported improved erections (RR = 3.12, 95 percent CI: 2.06-4.72).
Moxisylate versus PGE 1 (see PGE 1 versus moxisylate, above).
Moxisylate versus papaverine (see papaverine versus moxisylate, above).
Phentolamine plus PGE 1 versus PGE 1 . Two trials compared phentolamine plus PGE1
versus PGE1 alone for efficacy and/or harms (Aversa 1996; studies: a and b). 267
Harms. In the single trial that reported prolonged erection, 267 4.2 percent of participants in
each treatment group reported this adverse effect.
Efficacy. In the first trial, 54.2 percent of participants randomized to phentolamine plus PGE 1
reported improved erections versus 20.8 percent of those randomized to PGE 1 . 267 The
corresponding proportions reported for the other study were 60 versus 30 percent,
respectively. 267
Papaverine plus phentolamine versus placebo. One trial compared the efficacy and harms
of papaverine plus phentolamine versus placebo. 266
Harms. In total, 15 and 18.3 percent of the participants randomized to papaverine plus
phentolamine reported the occurrence of pain and prolonged erection, respectively. None of the
participants in placebo group experienced these adverse events.
Efficacy. In total, 56.7 percent of participants randomized to papaverine plus phentolamine
reported improved erections versus 0 percent of those randomized to placebo.
Papaverine plus phentolamine versus papaverine plus phentolamine plus sexual
counseling. One trial compared the efficacy and harms of papaverine plus phentolamine versus
papaverine plus phentolamine plus sexual counseling. 257
Harms. Results for harms in this study were pooled for the two treatment groups. 12 percent
of the men discontinued the treatment due to prolonged erection. Priapism was reported in three
(4.3 percent), hematoma in four (5.7 percent), and curvature of the penis in one participant (1.4
percent).
Efficacy. The mean values on a self-rated erections score (scale 0–100) for papaverine plus
phentolamine versus papaverine plus phentolamine plus sexual counseling groups were 79
versus 84 percent, respectively.
Trimix versus PGE 1 . Two trials compared the efficacy and harms of trimix versus PGE1
alone. 255,272 In the first trial, 32 men (mean age: 61 years) with ED of at least 6 months of
duration (etiology not reported) refractory to in-clinic injection of papaverine plus phentolamine,
were randomized in a crossover fashion to 40µg of PGE1 versus 17.64 mg papaverine plus 0.58
mg phentolamine plus 5.8µg PGE1. 272 Another trial enrolled 180 men (mean age: 51 years) with
ED at least 6 months’ duration, predominately of organic cause, of whom 20 percent had
complete ED. 255 Men in this trial were randomized in a crossover fashion to 20µg of PGE1 alone
versus one of nine different dose combinations of papaverine (range 5mg–20mg) plus
phentolamine (1 mg) plus PGE1 (2.5–10µg).
Harms. In the first trial, 12.5 percent of participants randomized to trimix reported pain
versus 40.6 percent of those allocated to PGE 1 . 272 . In the second trial, corresponding proportions
78